Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME Other HLA TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PRAME Other HLA TCR-T is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Anocca. It is designed to target the Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen that is highly expressed in a wide range of cancers but has limited expression in normal tissues. This specific program focuses on TCRs that recognize PRAME peptides presented on Human Leukocyte Antigen (HLA) alleles other than the common HLA-A*02:01, aiming to provide therapeutic options for a broader patient population. The therapy utilizes Anocca's proprietary platform to identify and validate high-precision TCRs for clinical use in treating melanoma, leukemia, and various solid tumors. The process involves genetically engineering a patient's own T cells to express these specific TCRs, which then recognize and eliminate PRAME-expressing tumor cells upon re-infusion.
- Other names
- Anocca-PRAME (additional HLA alleles) TCR-TAnocca-PRAME TCR-T cell therapy
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on PRAME Other HLA TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME Other HLA TCR-T.